BioSpace News Archive

Medtronic (NYSE:MDT) announced today that it has received CE (Conformité Européenne) Mark for the Affera™ Mapping and Ablation System, which includes the Sphere-9™ Catheter and the Affera™ Prism-1 Mapping Software.

Triumvira Immunologics today announced that the Company will be presenting preclinical and clinic data on its lead asset TAC01-HER2 for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando, April 14-19.

OnQuality Pharmaceuticals today announced it will present preclinical data for its two drug candidates, OQL025 and OQL06x, at the upcoming American Association for Cancer Research (AACR) annual meeting.

AbbVie announced the launch of a new documentary film, “Under My Skin: Untold Stories of Life with Eczema,” which debuted at South by Southwest® 2023 in Austin, Texas.

OncoNano Medicine, Inc. today announced three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023 at the Orange County Convention Center, Orlando, Florida.

ReCode Therapeutics announced today that the first healthy volunteer participants have been dosed in a Phase 1 clinical trial of RCT1100, a first-in-class, mRNA-based genetic medicine for the treatment of people with primary ciliary dyskinesia (PCD) caused by pathogenic mutations in the DNAI1 gene.

Nanite Inc. announced today an investment from the Cystic Fibrosis Foundation of up to $2 million to develop gene delivery technology.

Lantern Pharma Inc. today announced that the Company will present at the American Association for Cancer Research (AACR) Annual Meeting. Details on the AACR presentation are provided below.

Sporos BioDiscovery, Inc. today announced that it will present a poster highlighting preclinical data from the company’s novel, isoform selective TEAD inhibitor, SPR1, at the American Association for Cancer Research.

Perspectum has completed the second close of its $55 million Series C funding round.